Phaos Technology Holdings (Cayman) (POAS) Equity Ratio (2024 - 2025)

Phaos Technology Holdings (Cayman) (POAS) reported Equity Ratio of 2.72 for Q4 2025, down 167.65% quarter-over-quarter from 1.01 in Q2 2025.

Phaos Technology Holdings (Cayman) (POAS) Equity Ratio (2024 - 2025) Analysis & Trends

Phaos Technology Holdings (Cayman) has reported Equity Ratio for 2 years, with the latest figure at 2.72 in Q4 2025.

For the quarter ending Q4 2025, Equity Ratio changed N/A year-over-year to 2.72; the trailing twelve-month figure through Oct 2025 stood at 2.72 (changed N/A YoY), and the FY2025 full-year result was 1.01, down 280.18% from the prior year.
Equity Ratio for Q4 2025 stood at 2.72, down from 1.01 in the prior quarter.
The five-year high for Equity Ratio was 0.56 in Q2 2024, with the low at 2.72 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Ratio (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.47
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.50
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.54
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.59
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.78
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.42
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	0.45
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.29
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.67
10	Phaos Technology Holdings (Cayman)	682,234.12	627,245.12	-	-2.72

Download Data